Belgian ViroVet NV, which develops vaccines and antiviral drug for livestock, has named George Gunn as the newest member of its board of directors. Until early 2015, Gunn was CEO of Novartis Animal Health and a member of the global executive committee of Novartis.
Molecule prevents oedema
Latest NewsFrench researchers have identified a regulator which controls blood vessel permeability. Their findings open up the possibility to develop drugs preventing oedema that occur in large indications such as stroke or congestive heart failure.
Santhera: The doctor takes charge
AppointmentsDeveloper of treatments for neuromuscular and neuro-ophthalmological diseases Santhera Pharmaceuticals has hired Kristina Sjöblom Nygren as Chief Medical Officer and Head of Development.
Fighting AMR efficiently
Latest NewsVirovet: Veterinarian comes on board
AppointmentsuniQure gets FDA breakthrough status for AMT-060
Latest NewsDutch gene therapy specialist uniQure Biopharma BV will be able to rapidly develop its haemophilia B gene therapy AMT-060. Based on data of a Phase I/II safety study, the FDA granted breakthrough therapy designation for the new way to substitute the heritable lack of blood clotting factor IX.
IBAM completes US$690m deal
Latest NewsBelgian-headquartered IBA Molecular has completed the acquisition of British Mallinckrodt’s nuclear imaging business summing up to approximately US$690m.
€500m to push gene therapy
Latest NewsGerman Christian democrats have started the election year underpinning their intention to pump money into life science research and into its translation into products.
Making Brexit work for the life sciences sector
OpinionLike every sector of the UK economy, life sciences has been beset with uncertainty since the country voted to leave the European Union. Last week prime minister Theresa May finally gave us some clarity on her plans for Brexit, which will allow us to prepare for the future.
Johnson & Johnson to buy Actelion for US$30bn
Latest NewsFollowing a month-long take-over poker, J&J’s and Actelion’s boards have agreed to support an all-cash tender offer from J&J in which shareholders are set to receive US$280.08 per share and one share of NewCo, an R&D spin out to be led by Actelion CEO Paul Clozel. J&J will acquire at least 67% of Actelion’s shares and will hold 16% of NewCo with an option to further 16%.
HCC: resminostat boosts overall survival
Latest NewsGerman 4SC AG’s epigenetic cancer drug resminostat is back. What seemed to be a flop after Phase II failure has being transformed into a success story of personalised medicine. By accurate data analysis 4SC’s partner Yakult Honsha identified a subgroup in which the drug significantly improved outcomes for patients with hepatocellular carcinoma (HCC).